社会经济地位与胶质母细胞瘤生存的关联:意大利单中心前瞻性观察研究
多因素分析显示,较高收入与总生存显著相关(HR=0.623,95%CI 0.467-0.832,p=0.001),MGMT甲基化状态亦与总生存显著相关(HR=0.158,95%CI 0.082-0.304,P<0.001)。校正年龄、体能状态和手术范围后,较高收入的生存获益仍然存在(HR=0.641,95%CI 0.478-0.858,p=0.003),MGMT甲基化肿瘤同样保持生存优势(HR=0.167,95%CI 0.084-0.331,p<0.001)。结论提示,即使在提供全民免费医疗的意大利国家卫生服务体系下,社会经济地位仍是胶质母细胞瘤的重要预后决定因素。
要点
- 较高收入与胶质母细胞瘤患者总生存改善独立相关(HR=0.623,95%CI 0.467-0.832,p=0.001)。
- MGMT甲基化状态与总生存显著相关(HR=0.158,95%CI 0.082-0.304,P<0.001)。
- 校正年龄、体能状态和手术范围后,较高收入与MGMT甲基化的生存获益仍显著。
核心结论
- 社会经济地位是胶质母细胞瘤的重要预后决定因素,即使在提供全民覆盖的意大利国家卫生服务体系下仍然存在。
- 尽管追求医疗公平,社会经济差异仍然存在并可能影响临床结局。
研究设计与样本
- 前瞻性观察性研究,在意大利某脑肿瘤研究与治疗枢纽中心开展。
主要发现
- 多因素分析中,较高收入与总生存显著相关(HR=0.623,95%CI 0.467-0.832,p=0.001)。
- 多因素分析中,MGMT甲基化状态与总生存显著相关(HR=0.158,95%CI 0.082-0.304,P<0.001)。
- 校正年龄、体能状态和手术范围后,较高收入的生存获益仍然存在(HR=0.641,95%CI 0.478-0.858,p=0.003)。
- 校正年龄、体能状态和手术范围后,MGMT甲基化肿瘤的生存优势仍然存在(HR=0.167,95%CI 0.084-0.331,p<0.001)。
临床怎么用
- 在胶质母细胞瘤诊疗中,应将患者社会经济地位纳入预后评估与支持性照护的考量。
- 即使存在全民医疗保障,仍需关注社会经济差异对治疗可及性和临床结局的潜在影响。
局限性
- 社会经济地位仅采用收入等级衡量,未涵盖教育、职业等其他维度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To date, no prospective study has been conducted to investigate the role of socioeconomic status (SES) on clinical outcome of glioblastoma (GBM) in Italy, where there is a National Health Service that provides universal coverage regardless of the patient's economic status. METHODS: We performed a prospective observational study investigating the association between SES and survival in GBM patients at our institution, a hub centre for brain cancer research and treatment. We included GBM patients who underwent medical treatment or chemo-radiation between April 2017 and December 2017. The SES was measured using the income-brackets, attributed by the Italian Ministry of Finance on the basis of the income of the fiscal family unit, referring to the previous year. RESULTS: One hundred and six patients were included in the study. In multivariate analysis, overall survival (OS) correlated significantly with higher-income (HR = 0.623.95% CI 0.467-0.832; p = 0.001) and MGMT methylation status (HR = 0.158.95% CI 0.082-0.304; P < 0.001). When adjusted for age, performance status and extension of surgery, survival benefit remained superior for higher-income HR = 0.641 (95% CI 0.478-0.858; p = 0.003) and MGMT methylated tumours HR = 0.167 (95% CI 0.084-0.331; p < 0.001). CONCLUSIONS: SES is an important determinant of prognosis in GBM even in the Italian National Health Service, which provides universal, largely free and relatively comprehensive healthcare. Despite aspirations to achieve equality in healthcare, socioeconomic differences exist and may impact the clinical outcome.
引用
- Tosoni A, Gatto L, Franceschi E, et al. Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study. Eur J Cancer. 2021. PMID: 33486440. doi:10.1016/j.ejca.2020.12.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。